Yu dɔktɔ dɔn no se yu ɔ pɔsin we yu lɛk gɛt bɔdi kansa? Dɔn yu go dɔn yɛri di wɔd ‘kimotɛrapi’. Na nɔmal tin fɔ mek yu fred smɔl ɛn wɔri we yu yɛri dis. Bɔt if dɛn tɛl wi gud gud wan bɔt dɛn tritmɛnt ya , da fred de kin ridyus to bɔku bɔku wan. So, wan pan di impɔtant klas dɛm fɔ drɔgs we dɛn kin yuz fɔ mɛn kemo na in dɛn kɔl anthracyclines . Tide, wi go tɔk bɔt dis simpul wan ɛn di we we yu go ɔndastand.
Aw dis mɛrɛsin kin rili wok insay di bɔdi?
Fɔ tɔk am simpul wan, antrasayklin na wan kayn antibayɔtik we de ɛp fɔ kil di kansa sɛl dɛn. Bɔt dɛn nɔ tan lɛk di antibayɔtiks we wi kin tek fɔ di kɔmɔn kol ɔ flu. Na wan kayn fכns we dεn kכl Streptomyces, we de liv na di grכn de mek dεm.
Tink bɔt kansa sɛl lɛk fotokɔpi mashin we de mek kɔpi dɛn we nɔ gɛt kɔntrol. Dis mashin de kɔntinyu fɔ mek bɔku bɔku kɔpi dɛn fɔ insɛf. Dis na aw di tכmכro dεm de fכm εn gro. wetin antrasayklin dεm de du na we dεn de atak di ‘masta kכpi’ fכ DNA insay da kכpi mashin de. Dɔn dɛn nɔ kin ebul fɔ mek nyu kɔpi dɛn. Dat min se di kansa sɛl dɛn kin stɔp fɔ sheb ɛn gro kwik kwik wan.
Dɛn kin gi yu dis mɛrɛsin as injɛkshɔn ɔ as salin sɔlvushɔn insay wan vein (intravenous ɔ IV). Yu dɔktɔ go disayd ɔmɔs mɛrɛsin fɔ tek ɛn aw lɔng fɔ kɔntinyu fɔ tek di tritmɛnt bay di stej ɛn kɔndishɔn fɔ yu kansa.
Bɔku tɛm, we di bɔdi kansa dɔn bigin, dɛn kin du ɔpreshɔn fɔ pul di tumbu. Dɔn, dɛn kin gi kemotɛrapi fɔ pwɛl ɛni rili smɔl kansa sɛl we wi nɔ de si we kin stil lɛf na di bɔdi kpatakpata. Wi kin kɔl dis "Adjuvant Kemotɛrapi" . Dis kin ridyus di chans fɔ mek di kansa kam bak bad bad wan. Antrasayklin na wan pan di men klas dɛm fɔ drɔgs we dɛn kin yuz fɔ "Adjuvant Chemotherapy".
Aw di antrasayklin dɛn kin wok fayn?
Bɔku stɔdi dɛn dɔn sho se di kemotɛrapi we gɛt antrasayklin kin wok smɔl pas di wan dɛn we nɔ gɛt am.
Insay wan big stɔdi, dɛn bin sheb pas 4,000 uman dɛn we gɛt bɔdi kansa we bin dɔn bigin , we bin gɛt bɔku prɔblɛm fɔ gɛt am bak, to tu grup dɛn ɛn gi dɛn tu tritmɛnt dɛn.
1. Antrasayklin klas (TaxAC): .Dɛn bin gi dɛn pipul ya ɔda kemotɛrapi mɛrɛsin dɛn apat frɔm antrasayklin.
2. Grup we nɔ gɛt antrasayklin (TC): Dɛn bin gi dɛn pipul ya difrɛn kemotɛrapi drɔg kɔmbayn we nɔ gɛt antrasayklin.
Afta dɛn dɔn wach ɔl tu di grup dɛn fɔ lɛk 3 ia so, di wan dɛn we du di risach bin luk aw lɔng dɛn liv wɛl we di kansa nɔ kam bak. Di tin dɛn we dɛn bin fɛn na dɛn wan ya:
- Insay di anthracycline (TaxAC) grup, 92.4% pan di kansa nɔ bin kam bak.
- Insay di grup we nɔ bin gɛt antrasayklin (TC), 91.7% pan di kansa nɔ bin kam bak.
Dɛn rizɔlt ya sho se, pan ɔl we di difrɛns nɔ big, di tritmɛnt we gɛt antrasayklin kin stil ridyus smɔl di risk fɔ mek kansa kam bak.
Ɛni bad tin de we dis tritmɛnt kin du?
Yɛs, lɛk ɛni kemotɛrapi tritmɛnt, antrasayklin kin mek pɔsin gɛt sayd ɛfɛkt. Bɔt nɔto ɔlman kin gɛt dɛn, ɛn dɛn kin ebul fɔ kɔntrol bɔku pan dɛn. Yu dɔktɔ go ebul fɔ advays yu bɔt dɛn tin ya.
| Tayp fɔ di sayd ɛfɛkt | Sɔm sayn dɛn we kin apin |
|---|---|
| Mild to Moderate Sayd Ifɛkt dɛn | |
| Di tin dɛn we kɔmɔn | Vɔmit ɛn nɔs, kol ɛn fiva, dayarɛa, bɛlɛ pen, bɔdi pen, taya. |
| Skin ɛn nel dɛn | Skin rash, it, di nel we de chenj, di skin we de chenj. |
| Ɔda tin dɛn we kin apin | di kכla we di urine de chenj (rεdish), anorexia, fכ sεnsitiv to layt, sכt fכ mεnstral, εn di sεl dεm we de dכn pan man dεm. |
| I gɛt fɔ du wit blɔd | Blɔd we de kɔmɔt, di wayt blɔd sɛl dɛn we de go dɔŋ (we de mek di risk fɔ gɛt di sik bɔku), ɛn di bon mɛro we de stɔp. |
Yu fɔ no bɔt di bad bad tin dɛn we kin apin to yu
Di men ɛn siriɔs sayd ɛfɛkt fɔ dɛn mɛrɛsin ya na di risk fɔ mek yu at pwɛl. We dɛn yuz dɛn mɛrɛsin ya fɔ lɔng tɛm, i kin gɛt prɔblɛm dɛn lɛk at pwɛl, we kin mek di at mɔsul wik. Dɔn bak, sɔm antrasayklin dɛn kin gɛt smɔl risk fɔ gɛt ɔda kayn kansa lɛk lukimiya, we nɔ kin apin so ɔltɛm.
Bikɔs ɔf dɛn prɔblɛm ya, yu dɔktɔ we de mɛn yu kansa ɛn dɔktɔ we de mɛn yu at go wok togɛda fɔ wach aw yu at de wok ɔlsay na yu tritmɛnt fɔ mek yu nɔ gɛt ɛnitin we go pwɛl yu at. So nɔ fred dis.
Dɛn tin ya kin fayn fɔ sɔm kayn bɔdi kansa?
Yɛs. Nɔto ɔl di bɔdi kansa na di sem. So, yu dɔktɔ go pik di tritmɛnt we go fayn fɔ yu. Dis go dipen pan sɔm tin dɛn:
- Stej we kansa gɛt
- If di kansa de fil fɔ di ɔmon dɛn (Hormone-receptor status) .
- HER2 stetɔs fɔ kansa
- If di kansa dɔn spre to di limf no dɛm
- Yu ej ɛn ɔl yu wɛlbɔdi
Fɔ ɛgzampul, if pɔsin dɔn pas 60 ia, i gɛt ay blɔd prɛshɔn, ɛn i dɔn gɛt at sik, di dɔktɔ go mɔs tɛl am fɔ tek tritmɛnt we nɔ gɛt antrasayklin.
Risach dɔn sho se pipul dɛn we gɛt agresiv kayn kansa, lɛk triplɛ-nɛgitiv, ɛn di wan dɛn we dɛn kansa dɔn spre to di limf no dɛm kin bɛnifit mɔ frɔm tritmɛnt dɛn we gɛt antrasayklin.
Wetin kin apin if di kansa nɔ ebul fɔ tek antrasayklin?
Sɔmtɛm, as tɛm de go, di kansa sɛl dɛn kin ebul fɔ bia wit dɛn mɛrɛsin ya, we min se di mɛrɛsin dɛn nɔ kin wok. Nɔ wɔri if dis apin. If dat apin, bɔku ɔda mɛrɛsin ɛn tritmɛnt dɛn de we yu dɔktɔ kin yuz.
Sɔm ɛgzampul dɛn na:
- Kapɛsitabin (Xeloda) we dɛn kɔl .
- Ɛribulin (Halaven) .
- Gemsitabin (Gemzar) we dɛn kɔl Gemsitabin (Gemzar) .
- Vinorelbin (Navelbin) we dɛn kɔl .
- Mɔdan drɔgs lɛk antibodi drɔg kɔnjɔg
Advans tritmɛnt dɛn de bak we dɛn kin gɛt, lɛk targeted drug therapy ɛn immunotherapy. Di tin we impɔtant pas ɔl na fɔ kɔntinyu fɔ tɔk to yu mɛdikal tim ɔltɛm.
Mɛsej we dɛn kin kɛr go na os
- Antrasayklin na wan klas we rili pawaful ɛn we de wok fayn we dɛn kin yuz fɔ mɛn bɔdi kansa.
- di men wok we dεn de du na fכ afekt di DNA fכ di kεnsar sεl dεm, fכ stכp dεm fכ divayd εn gro.
- Lɛk ɔl di mɛrɛsin dɛn, sɔm bad tin dɛn de we kin apin to pɔsin. Ɛspɛshali bikɔs ɔf di tin dɛn we kin apin to di at, i rili impɔtant fɔ mek dɛn gɛt tritmɛnt ɔnda di dɔktɔ we de kia fɔ am gud gud wan.
- Di disayd if dɛn go gi yu antrasayklin ɔ nɔ go gi yu, na afta dɛn dɔn tink bɔt bɔku tin dɛn, lɛk di kayn kansa we yu gɛt ɛn aw yu gɛt wɛlbɔdi.
- Nɔ ɛva fred fɔ tɔk to yu dɔktɔ opin wan bɔt yu tritmɛnt, sayd ɛfɛkt, ɔ ɛni kwɛstyɔn, fred, ɔ wɔri we yu go gɛt. Fɔ no di rayt we na di bɛst wɛpɔn fɔ win dis fɛt.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt